Home | Welcome to Contract Pharma   
Last Updated Tuesday, November 25 2014
Print

Financial Report: Parexel



By Gil Roth



Published January 30, 2014
Financial Report: Parexel 2Q14

2Q Revenues: $574 million (+19%)

2Q Earnings: $28 million (+33%)

HY Revenues: $1.1 billion (+17%)

HY Earnings: $54 million (+49%)

Comments: Service revenues in 2Q14 grew 15% to $487 million, with recent acquisitions contributing $14 million to that pool. In the quarter, Clinical Research Services accounted for $364 million (+14%), Consulting and Medical Communications were $56 million (+13%), and the Perceptive Informatics group added $68 million (+30%). Backlog at the end of the quarter was $4.8 billion (+6% year-over-year). The reported backlog included gross new business wins in the quarter of $836 million, cancellations of $181.4 million, and a positive impact from foreign exchange rates of $11.1 million. The net book-to-bill ratio was 1.34 in the quarter.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On